Effects of training oncology physicians advising patients on complementary and integrative therapies on patient‐reported outcomes: 2‐year follow‐up of the multi‐center, cluster‐randomized KOKON‐KTO study
Open Access
- 19 July 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (14) , e70008
Abstract
Purpose: Many cancer patients wish for complementary and integrative medicine (CIM) consultations led by their oncology physician. Within the KOKON‐KTO study, oncology physicians in the intervention group were trained in a blended learning to provide CIM consultations to their cancer patients in addition to distributing a leaflet about CIM websites. Control oncology physicians only distributed the leaflet. The training showed positive effects on the patient‐level. As of now, no consistent evidence exists on the long‐term effects of such one‐time‐only CIM consultation during cancer treatment.Methods: In the KOKON‐KTO follow‐up study, cancer patients previously participating in the KOKON‐KTO study (intervention group:IG and control group: CG) received, at least 24 months later, a follow‐up questionnaire by post, evaluating long‐term effects of the KOKON‐KTO consultation using the measures provided in the original study (patient‐physician communication (EORTC‐QLQ‐COMU2), satisfaction with cancer treatment (PS‐CaTE), CIM disclosure with healthcare provider (HCP), and need for CIM consultation during cancer therapy).Results: In total, 102 cancer patients participated in the follow‐up study (IG n = 62; CG n = 40). The overall reponse rate was around 36% (IG: 48.4%; CG: 23.7%). In the follow‐up study, differences between groups had increased and were still shown (EORTC‐QLQ‐COMU26, 0–100 point scale, ≥10‐point‐group difference) in some subscales: patient's active behavior (in means; IG:73.6 (95% CI, 63.8–83.5); CG:61.1 (95% CI, 52.4–69.8)); clinician‐patient relationship (IG:80.9 (95% CI, 71.8–90.0); CG:68.7 (95% CI, 59.3–78.0)). For some outcomes, differences decreased over time (e.g., EORTC‐QLQ‐COMU26 subscales “takes into account patient's preference” and “corrects misunderstandings”). More patients in the CG used CIM without oncology physicians' knowledge (IG: 13.7%, CG: 24.0%).Conclusion: This study presents first findings that one‐time‐only CIM consultations may enhance patient‐physican relationship and CIM disclosure long‐term. To further support cancer patients' in their wish for CIM consultations, training programs should provide oncology physicians with CIM competencies for different cancer stages including cancer survivors.Keywords
Funding Information
- Deutsche Krebshilfe (109863, 70112369)
This publication has 26 references indexed in Scilit:
- Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable CancersJAMA Oncology, 2018
- Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Cancer and Complementary Therapies: Current Trends in Survivors’ Interest and UseIntegrative Cancer Therapies, 2018
- Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology settingJournal of Cancer Research and Clinical Oncology, 2017
- Integrative Oncology Outpatient Consultations: Long-Term Effects on Patient-Reported Symptoms and Quality of LifeJournal of Cancer, 2017
- EORTC QLQ-COMU26: a questionnaire for the assessment of communication between patients and professionals. Phase III of the module development in ten countriesSupportive Care in Cancer, 2016
- National Survey of US Oncologists' Knowledge, Attitudes, and Practice Patterns Regarding Herb and Supplement Use by Patients With CancerJournal of Clinical Oncology, 2014
- Decision-making about complementary and alternative medicine by cancer patients: integrative literature review2014
- How Many Cancer Patients Use Complementary and Alternative MedicineIntegrative Cancer Therapies, 2011
- Psychometric assessment and application of a questionnaire measuring patient satisfaction with information on cancer treatmentPharmacy World & Science, 2005